亨迪药业 reported revenue of ¥0.25B for the period ended 2026-06-30, +5.4% year on year. Net income was ¥0.03B, a 12.2% net margin on a 23.5% gross margin. The largest revenue line is 抗炎类 at 63% of the total. Free cash flow for the period was ¥0.02B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.25B | +5.4% |
| Gross profit | ¥0.06B | — |
| Operating income | ¥0.03B | — |
| Net income | ¥0.03B | +62.5% |
| Gross margin | 23.5% | Net margin 12.2% |
| Revenue Q/Q | +6.0% | — |
| Segment | Revenue | Share |
|---|---|---|
| 抗炎类 | ¥0.15B | 62.5% |
| 心血管类 | ¥0.04B | 15.9% |
| 其他 | ¥0.03B | 12.6% |
| 抗肿瘤类 | ¥0.02B | 9.0% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.19B | 76.5% |
| R&D | ¥0.01B | 5.1% |
| SG&A | ¥0.03B | 14.0% |
| Tax & other | ¥0.00B | 1.3% |
| Item | Amount |
|---|---|
| Total assets | ¥2.39B |
| Total liabilities | ¥0.11B |
| Shareholders' equity | ¥2.28B |
| Equity / assets | 95.2% |
| Operating cash flow | ¥0.04B |
| Capital expenditure | ¥0.02B |
| Free cash flow | ¥0.02B |
| Cash conversion (OCF / net income) | 108% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
联盛化学 ・ 观想科技 ・ 中汽股份 ・ 万凯新材 ・ 铜冠铜箔 ・ 华是科技 ・ 腾远钴业 ・ 亚香股份 ・ 光庭信息 ・ 浙江恒威 ・ 中荣股份 ・ 恒勃股份
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies